Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 470.83M | 491.37M | 406.46M | 415.86M | 276.05M |
Gross Profit | 367.75M | 389.20M | 314.00M | 324.34M | 227.28M |
EBITDA | -612.96M | -547.84M | -999.37M | -324.03M | -152.83M |
Net Income | -714.31M | -703.75M | -1.12B | -371.39M | -182.87M |
Balance Sheet | |||||
Total Assets | 3.25B | 4.41B | 5.28B | 5.11B | 4.32B |
Cash, Cash Equivalents and Short-Term Investments | 305.70M | 781.64M | 1.88B | 2.96B | 2.75B |
Total Debt | 369.09M | 826.19M | 899.64M | 70.78M | 32.76M |
Total Liabilities | 1.04B | 1.49B | 1.65B | 477.61M | 461.19M |
Stockholders Equity | 2.21B | 2.92B | 3.61B | 4.55B | 3.82B |
Cash Flow | |||||
Free Cash Flow | -17.82M | -872.93M | -908.23M | -602.08M | -361.05M |
Operating Cash Flow | 23.74M | -610.02M | -729.46M | -456.92M | -237.00M |
Investing Cash Flow | -19.90M | -346.86M | -1.07B | -653.04M | -297.94M |
Financing Cash Flow | -487.34M | -173.99M | 635.14M | 1.39B | 927.75M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
69 Neutral | €6.82B | 61.89 | 3.22% | ― | 45.82% | ― | |
60 Neutral | HK$1.46B | ― | -1.28% | ― | 17.45% | 85.71% | |
60 Neutral | HK$15.14B | 5.56 | -7.43% | 4.30% | 11.60% | -21.06% | |
52 Neutral | HK$1.08B | ― | -8.64% | ― | -20.99% | 45.74% | |
51 Neutral | €4.27B | ― | -10.43% | ― | 36.76% | 42.89% | |
50 Neutral | HK$1.16B | ― | -27.82% | ― | -6.12% | 0.43% | |
47 Neutral | HK$2.12B | ― | -2.19% | ― | 5.32% | 89.43% |
Venus Medtech (Hangzhou) Inc. announced that all resolutions proposed at its 2024 Annual General Meeting (AGM) were approved. The AGM, held on June 27, 2025, included the election of a new chairman and board members, re-appointment of auditors, and approval of the 2024 annual report and profit distribution plan. The successful passing of these resolutions reflects strong shareholder support and positions the company for continued governance and operational stability.
Venus Medtech (Hangzhou) Inc. has announced the composition of its board of directors and their respective roles within various board committees. This update reflects the company’s commitment to strong corporate governance and strategic leadership, which is crucial for maintaining its competitive position in the medical technology sector.
Venus Medtech (Hangzhou) Inc. has outlined the terms of reference for its Nomination Committee, a specialized committee under the Board of Directors. The committee, consisting of at least three directors with a majority of independent non-executive directors, is tasked with ensuring diversity and suitable qualifications in board member selection. This initiative is expected to enhance the company’s governance structure and align with its corporate strategy, potentially impacting its industry positioning by promoting a diverse and skilled leadership team.
Venus Medtech (Hangzhou) Inc. has announced its 2024 Annual General Meeting scheduled for June 27, 2025, where key resolutions will be discussed and approved. These include the approval of the 2024 annual report, re-election of directors, appointment of auditors, and granting mandates for share issuance and repurchase, reflecting the company’s ongoing strategic management and governance efforts.
Venus Medtech (Hangzhou) Inc. has announced the proposed re-election and appointment of directors and supervisors for the third session of its Board and Supervisory Committee. The company plans to re-elect and appoint a total of eight directors and three supervisors, with the re-election proposal set to be approved at the 2024 annual general meeting. This strategic move is expected to ensure continuity in leadership and governance, potentially impacting the company’s operational stability and stakeholder confidence.